<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04639258</url>
  </required_header>
  <id_info>
    <org_study_id>D00266108</org_study_id>
    <nct_id>NCT04639258</nct_id>
  </id_info>
  <brief_title>Medtronic Evolut™ EXPAND TAVR I Feasibility Study</brief_title>
  <official_title>Medtronic Evolut™ EXPAND TAVR I Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Cardiovascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Cardiovascular</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to obtain safety and effectiveness data of the Medtronic Evolut™&#xD;
      PRO+ TAVR System for the treatment of severe, asymptomatic aortic stenosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Single-arm, descriptive, multi-center, international&#xD;
&#xD;
      All subjects will be treated with a Medtronic Evolut™ PRO+ TAVR System. Subject follow-ups&#xD;
      will be conducted at pre and post-procedure, discharge, 30 days, 6 months, and annually&#xD;
      through 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 31, 2021</start_date>
  <completion_date type="Anticipated">December 2027</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All-cause and cardiovascular mortality</measure>
    <time_frame>30 days</time_frame>
    <description>Rate of all-cause and cardiovascular mortality</description>
  </primary_outcome>
  <primary_outcome>
    <measure>All-cause and cardiovascular mortality</measure>
    <time_frame>6 months</time_frame>
    <description>Rate of all-cause and cardiovascular mortality</description>
  </primary_outcome>
  <primary_outcome>
    <measure>All stroke (disabling and non-disabling)</measure>
    <time_frame>30 days</time_frame>
    <description>Rate of disabling and non-disabling stroke</description>
  </primary_outcome>
  <primary_outcome>
    <measure>All stroke (disabling and non-disabling)</measure>
    <time_frame>6 months</time_frame>
    <description>Rate of disabling and non-disabling stroke</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Myocardial infarction (periprocedural and spontaneous)</measure>
    <time_frame>30 days</time_frame>
    <description>Rate of periprocedural and spontaneous myocardial infarction</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Myocardial infarction (periprocedural and spontaneous)</measure>
    <time_frame>6 months</time_frame>
    <description>Rate of periprocedural and spontaneous myocardial infarction</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Acute kidney injury</measure>
    <time_frame>30 days</time_frame>
    <description>Rate of acute kidney injury</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Acute kidney injury</measure>
    <time_frame>6 months</time_frame>
    <description>Rate of acute kidney injury</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major vascular complications</measure>
    <time_frame>30 days</time_frame>
    <description>Rate of major vascular complications</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major vascular complications</measure>
    <time_frame>6 months</time_frame>
    <description>Rate of major vascular complications</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Life-threatening bleed</measure>
    <time_frame>30 days</time_frame>
    <description>Rate of life-threatening (or disabling) bleed</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Life-threatening bleed</measure>
    <time_frame>6 months</time_frame>
    <description>Rate of life-threatening (or disabling) bleed</description>
  </primary_outcome>
  <primary_outcome>
    <measure>New permanent pacemaker implantation (PPI)</measure>
    <time_frame>30 days</time_frame>
    <description>Rate of new permanent pacemaker implantation (excludes patients with pre-existing pacemakers at baseline)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>New permanent pacemaker implantation (PPI)</measure>
    <time_frame>6 months</time_frame>
    <description>Rate of new permanent pacemaker implantation (excludes patients with pre-existing pacemakers at baseline)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>New intraventricular conduction delays</measure>
    <time_frame>30 days</time_frame>
    <description>Rate of new intraventricular conduction delays (excludes patients with intraventricular conduction delays at baseline)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>New intraventricular conduction delays</measure>
    <time_frame>6 months</time_frame>
    <description>Rate of new intraventricular conduction delays (excludes patients with intraventricular conduction delays at baseline)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>New-onset atrial fibrillation</measure>
    <time_frame>30 days</time_frame>
    <description>Rate of new-onset atrial fibrillation (excludes patients with atrial fibrillation at baseline)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>New-onset atrial fibrillation</measure>
    <time_frame>6 months</time_frame>
    <description>Rate of new-onset atrial fibrillation (excludes patients with atrial fibrillation at baseline)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Valve-related dysfunction requiring repeat procedure</measure>
    <time_frame>30 days</time_frame>
    <description>Rare of valve-related dysfunction requiring repeat procedure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Valve-related dysfunction requiring repeat procedure</measure>
    <time_frame>6 months</time_frame>
    <description>Rare of valve-related dysfunction requiring repeat procedure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Device success (VARC-2)</measure>
    <time_frame>Through 5 years post-implant</time_frame>
    <description>The VARC-2 definition of device success is absence of procedural mortality, correct positioning of a single prosthetic heart valve into the proper anatomical location, intended performance of the prosthetic heart valve, defined as the absence of patient-prosthesis-mismatch and mean aortic valve gradient less than 20 mmHg (or peak velocity &lt;3 m/sec), and absence of moderate or severe prosthetic valve regurgitation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiovascular and heart failure hospitalizations</measure>
    <time_frame>30 days</time_frame>
    <description>Rate of cardiovascular and heart failure hospitalizations</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiovascular and heart failure hospitalizations</measure>
    <time_frame>6 months</time_frame>
    <description>Rate of cardiovascular and heart failure hospitalizations</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Heart failure events</measure>
    <time_frame>30 days</time_frame>
    <description>Rate of heart failure events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Heart failure events</measure>
    <time_frame>6 months</time_frame>
    <description>Rate of heart failure events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hemodynamic performance metrics (mean aortic gradient) by Doppler echocardiography</measure>
    <time_frame>Discharge (12 hours to 7 days post-procedure)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Hemodynamic performance metrics (mean aortic gradient) by Doppler echocardiography</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Hemodynamic performance metrics (mean aortic gradient) by Doppler echocardiography</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Hemodynamic performance metrics (effective orifice area) by Doppler echocardiography</measure>
    <time_frame>Discharge (12 hours to 7 days post-procedure)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Hemodynamic performance metrics (effective orifice area) by Doppler echocardiography</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Hemodynamic performance metrics (effective orifice area) by Doppler echocardiography</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Hemodynamic performance metrics (degree of total, para, and transvalvular prosthetic regurgitation) by Doppler echocardiography</measure>
    <time_frame>Discharge (12 hours to 7 days post-procedure)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Hemodynamic performance metrics (degree of total, para, and transvalvular prosthetic regurgitation) by Doppler echocardiography</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Hemodynamic performance metrics (degree of total, para, and transvalvular prosthetic regurgitation) by Doppler echocardiography</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Hemodynamic performance metrics (incidence of moderate and severe patient-prosthesis mismatch) by Doppler echocardiography</measure>
    <time_frame>Discharge (12 hours to 7 days post-procedure)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Hemodynamic performance metrics (incidence of moderate and severe patient-prosthesis mismatch) by Doppler echocardiography</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Hemodynamic performance metrics (incidence of moderate and severe patient-prosthesis mismatch) by Doppler echocardiography</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in New York Heart Association (NYHA) functional classification</measure>
    <time_frame>30 days and 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in six-minute walk test (6MWT)</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in health-related Quality of Life (QoL) as assessed by Kansas City Cardiomyopathy Questionnaire (KCCQ)</measure>
    <time_frame>30 days and 6 months</time_frame>
    <description>KCCQ quantifies physical function, symptoms, social function, self-efficiency, knowledge, and quality of life. Scores are transformed to a range of 0-100, in which higher scores reflect better health status.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in left ventricular ejection fraction (LVEF)</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in global longitudinal strain (GLS)</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in left ventricular filling pressure (E:e')</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in stroke volume index (SVI)</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in NT-pro B-type natriuretic peptide (NT-proBNP)</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <other_outcome>
    <measure>All-cause and cardiovascular mortality</measure>
    <time_frame>Annually through 5 years</time_frame>
    <description>Rate of all-cause and cardiovascular mortality</description>
  </other_outcome>
  <other_outcome>
    <measure>All stroke (disabling and non-disabling)</measure>
    <time_frame>Annually through 5 years</time_frame>
    <description>Rate of disabling and non-disabling strokes</description>
  </other_outcome>
  <other_outcome>
    <measure>Cardiovascular and heart failure hospitalizations</measure>
    <time_frame>Annually through 5 years</time_frame>
    <description>Rate of cardiovascular and heart failure hospitalizations</description>
  </other_outcome>
  <other_outcome>
    <measure>Heart failure events</measure>
    <time_frame>Annually through 5 years</time_frame>
    <description>Rate of heart failure events</description>
  </other_outcome>
  <other_outcome>
    <measure>New York Heart Association (NYHA) functional classification</measure>
    <time_frame>30 days, 6 months, and annually through 5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in New York Heart Association (NYHA) functional classification</measure>
    <time_frame>Annually through 5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Health-related Quality of Life (QoL) as assessed by Kansas City Cardiomyopathy Questionnaire (KCCQ)</measure>
    <time_frame>Annually through 5 years</time_frame>
    <description>KCCQ quantifies physical function, symptoms, social function, self-efficiency, knowledge, and quality of life. Scores are transformed to a range of 0-100, in which higher scores reflect better health status.</description>
  </other_outcome>
  <other_outcome>
    <measure>Hemodynamic performance metrics (mean aortic gradient) by Doppler echocardiography</measure>
    <time_frame>Annually through 5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Hemodynamic performance metrics (effective orifice area) by Doppler echocardiography</measure>
    <time_frame>Annually through 5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Hemodynamic performance metrics (degree of total, para, and transvalvular prosthetic regurgitation) by Doppler echocardiography</measure>
    <time_frame>Annually through 5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Hemodynamic performance metrics (incidence of moderate and severe patient-prosthesis mismatch) by Doppler echocardiography</measure>
    <time_frame>Annually through 5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Prosthetic valve thrombosis</measure>
    <time_frame>30 days, 6 months, and annually through 5 years</time_frame>
    <description>Rate of prosthetic valve thrombosis</description>
  </other_outcome>
  <other_outcome>
    <measure>Prosthetic valve endocarditis</measure>
    <time_frame>30 days, 6 months, and annually through 5 years</time_frame>
    <description>Rate of prosthetic valve endocarditis</description>
  </other_outcome>
  <other_outcome>
    <measure>Bioprosthetic valve dysfunction (BVD)</measure>
    <time_frame>30 days, 6 months, and annually through 5 years</time_frame>
    <description>Rate of bioprosthetic valve dysfunction (BVD)</description>
  </other_outcome>
  <other_outcome>
    <measure>Bioprosthetic valve failure (BVF)</measure>
    <time_frame>30 days, 6 months, and annually through 5 years</time_frame>
    <description>Rate of bioprosthetic valve failure (BVF)</description>
  </other_outcome>
  <other_outcome>
    <measure>Valve-related dysfunction requiring repeat procedure</measure>
    <time_frame>Annually through 5 years</time_frame>
    <description>Rate of valve-related dysfunction requiring repeat procedure</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <arm_group>
    <arm_group_label>Medtronic Evolut™ PRO+ System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All study subjects will be treated with the Medtronic Evolut™ PRO+ TAVR System.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Medtronic Evolut™ PRO+ System</intervention_name>
    <description>TAVR treatment with Medtronic Evolut™ PRO+ System</description>
    <arm_group_label>Medtronic Evolut™ PRO+ System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Severe aortic stenosis, defined as: Aortic valve area ≤ 1.0 cm^2, or aortic valve area&#xD;
             index ≤ 0.6 cm^2/m^2, and mean gradient ≥ 40 mmHg or Vmax ≥ 4.0 m/sec&#xD;
&#xD;
          -  Subject denies symptoms attributable to aortic stenosis, including but not limited to:&#xD;
&#xD;
               -  Dyspnea on rest or exertion&#xD;
&#xD;
               -  Angina&#xD;
&#xD;
               -  Syncope in the absence of another identifiable cause&#xD;
&#xD;
               -  Fatigue&#xD;
&#xD;
               -  Left Ventricular Ejection Fraction (LVEF) &gt;50%&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt;65 years&#xD;
&#xD;
          -  Class I indication for cardiac surgery&#xD;
&#xD;
          -  Bicuspid, unicuspid, or quadricuspid aortic valve&#xD;
&#xD;
          -  In need of and suitable for coronary revascularization&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Sorajja, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Allina Health System</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Josep Rodes-Cabau, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondation IUCPQ</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Evolut EXPAND TAVR I Feasibility Study Team</last_name>
    <phone>7635266237</phone>
    <email>rs.newtavrindications@medtronic.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rachel Vasseur</last_name>
    <email>rachel.s.vasseur@medtronic.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Los Robles Hospital &amp; Medical Center</name>
      <address>
        <city>Thousand Oaks</city>
        <state>California</state>
        <zip>91360</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mane Arabyan</last_name>
    </contact>
    <investigator>
      <last_name>Gregory Fontana, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwell Health</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030-3816</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristine McGowan</last_name>
    </contact>
    <investigator>
      <last_name>Bruce Rutkin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Pinnacle Harrisburg Campus</name>
      <address>
        <city>Wormleysburg</city>
        <state>Pennsylvania</state>
        <zip>17043</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Regina Hollister</last_name>
    </contact>
    <investigator>
      <last_name>Hemal Gada, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aurora Saint Luke's Medical Center</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jodi Kressa</last_name>
    </contact>
    <investigator>
      <last_name>Tanvir Bajwa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brianna Davidson</last_name>
    </contact>
    <investigator>
      <last_name>Tony Walton</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Waikato Hospital</name>
      <address>
        <city>Hamilton</city>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gypsy Francis</last_name>
    </contact>
    <investigator>
      <last_name>Sanjeevan Pasupati</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>New Zealand</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 5, 2020</study_first_submitted>
  <study_first_submitted_qc>November 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2020</study_first_posted>
  <last_update_submitted>October 15, 2021</last_update_submitted>
  <last_update_submitted_qc>October 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

